{
    "clinical_study": {
        "@rank": "100738", 
        "arm_group": [
            {
                "arm_group_label": "WR 279,396", 
                "arm_group_type": "Experimental", 
                "description": "(Paromomycin and Gentamicin Topical Cream)"
            }, 
            {
                "arm_group_label": "Paromomycin", 
                "arm_group_type": "Experimental", 
                "description": "Paromomycin alone"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is a pivotal Phase 3, randomized, double-blind, 3-site, two-group trial assessing\n      the efficacy and safety of WR 279,396 Topical Cream and Paromomycin Alone Topical Cream in\n      subjects with CL in Panama. The primary objective of this study is to determine if WR\n      279,396 results in statistically superior final clinical cure rates of an index lesion when\n      compared with Paromomycin Alone for the treatment of CL in Panama expected to be caused by L\n      panamensis."
        }, 
        "brief_title": "Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Cutaneous Leishmaniasis", 
        "condition_browse": {
            "mesh_term": [
                "Leishmaniasis", 
                "Leishmaniasis, Cutaneous"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female at least 5 years-of-age\n\n          -  Subject or legal guardian able to give written informed consent or assent, as\n             appropriate\n\n          -  Diagnosis of CL in at least one lesion by at least one of the following methods: 1)\n             positive culture for promastigotes or 2) microscopic identification of amastigotes in\n             stained lesion tissue\n\n          -  At least one ulcerative lesion \u2265 1 cm and \u2264 5 cm that has a diagnosis of CL\n\n          -  Willing to forego other forms of treatments for CL including other investigational\n             treatments during the study\n\n          -  In the opinion of the investigator, subject (or their legal guardian), subject is\n             capable of understanding and complying with the protocol\n\n          -  If female and of child-bearing potential, must have a negative serum pregnancy test\n             during screening and agree to use an acceptable method of birth control during the\n             treatment phase and for 1 week after treatment is completed\n\n        Exclusion Criteria:\n\n          -  Lesion due to leishmania that involves the nasal or oral mucosa or any signs of\n             mucosal disease that might be due to Leishmania\n\n          -  Only a single lesion on the ear with erosive cartilage\n\n          -  Signs and symptoms of disseminated disease in the opinion of the investigator\n\n          -  More than 10 lesions\n\n          -  Female who is breast-feeding\n\n          -  Significant organ abnormality, chronic disease such as diabetes, severe hearing loss,\n             evidence of renal or hepatic dysfunction, or creatinine, aspartate aminotransferase\n             (AST), or alanine aminotransferase (ALT) greater than 15% above the upper limit of\n             normal (ULN) as defined by the clinical laboratory defined normal ranges\n\n          -  Received treatment for leishmaniasis including any medication with pentavalent\n             antimony including sodium stibogluconate (Pentostam\u2122), meglumine antimoniate\n             (Glucantime\u2122); amphotericin B (including liposomal amphotericin B and amphotericin B\n             deoxycholate); or other medications containing paromomycin (administered parenterally\n             or topically) or methylbenzethonium chloride (MBCL); gentamicin; fluconazole;\n             ketoconazole; pentamidine; miltefosine, azithromycin or allopurinol that was\n             completed within 56 days of starting study treatments\n\n          -  History of known or suspected hypersensitivity or idiosyncratic reactions to\n             aminoglycosides"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "5 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01790659", 
            "org_study_id": "S-12-21"
        }, 
        "intervention": [
            {
                "arm_group_label": "WR 279,396", 
                "description": "WR 279,396 is a topical cream of paromomycin 15% and gentamicin 0.5%", 
                "intervention_name": "WR 279,396", 
                "intervention_type": "Drug", 
                "other_name": "Paromomycin/Gentamicin topical cream"
            }, 
            {
                "arm_group_label": "Paromomycin", 
                "description": "Paromomycin alone", 
                "intervention_name": "Paromomycin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Gentamicins", 
                "Paromomycin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "leishmaniasis", 
            "cutaneous leishmaniasis", 
            "Leishmania panamensis", 
            "L panamensis", 
            "Paromomycin", 
            "Paromomycin/Gentamicin"
        ], 
        "lastchanged_date": "April 8, 2014", 
        "location": {
            "contact": {
                "last_name": "Zeus Capitan, MSc", 
                "phone": "507-527-4815"
            }, 
            "contact_backup": {
                "last_name": "Vanessa Almengor, MSc", 
                "phone": "507-527-4815"
            }, 
            "facility": {
                "address": {
                    "city": "Panama City", 
                    "country": "Panama"
                }, 
                "name": "Instituto Conmemorativo Gorgas de Estudios de la Salud,"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Panama"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-blind, Pivotal Phase 3 Study of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Alone Topical Cream for the Treatment of Cutaneous Leishmaniasis in Panama", 
        "overall_official": {
            "affiliation": "Instituto Conmemorativo Gorgas de Estudios de la Salud", 
            "last_name": "Nestor Sosa, MD, FACP", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary efficacy endpoint is percentage of subjects with final clinical cure. Final clinical cure is defined as follows:\nSubject has initial clinical cure (100% re-epithelialization of index lesion by nominal Day 63); OR,\nSubject has initial clinical improvement (> 50% re-epithelialization of index lesion by nominal Day 63) followed by 100% re-epithelialization of the index lesion on or before nominal Day 100; AND,\nSubject has no relapse of index lesion.", 
            "measure": "final clinical cure change from baseline", 
            "safety_issue": "No", 
            "time_frame": "baseline (before the start of treatment), and on Study Days 20, 35 \u00b1 2 days, 49 \u00b1 4 days, 63 \u00b1 7 days, 100 \u00b1 14 days, and 168 \u00b1 14 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01790659"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "\u2022\tPercentage of subjects with all lesions cured, defined as: Final clinical cure as defined in primary objective (which is based solely on the index lesion); AND, Cure of all other lesions by nominal Day 100 (100% re-epithelialization of all ulcerated lesions and resolution of all other types of lesions)", 
                "measure": "Percentage of subjects with all lesions cured", 
                "safety_issue": "No", 
                "time_frame": "baseline (before the start of treatment), and on Study Days 20, 35 \u00b1 2 days, 49 \u00b1 4 days, 63 \u00b1 7 days, 100 \u00b1 14 days, and 168 \u00b1 14 days"
            }, 
            {
                "measure": "Percentage of all lesions cured at Day 168 (ignores per subject cure rate)", 
                "safety_issue": "No", 
                "time_frame": "Day 168"
            }, 
            {
                "measure": "Area of ulceration of the index lesion at each measurement time point", 
                "safety_issue": "No", 
                "time_frame": "baseline (before the start of treatment), and on Study Days 20, 35 \u00b1 2 days, 49 \u00b1 4 days, 63 \u00b1 7 days, 100 \u00b1 14 days, and 168 \u00b1 14 days"
            }, 
            {
                "measure": "Area of ulceration all treated lesions at each measurement time point", 
                "safety_issue": "No", 
                "time_frame": "baseline (before the start of treatment), and on Study Days 20, 35 \u00b1 2 days, 49 \u00b1 4 days, 63 \u00b1 7 days, 100 \u00b1 14 days, and 168 \u00b1 14 days"
            }, 
            {
                "description": "(cure is defined as 100% re-epithelialization of an ulcerated lesion)", 
                "measure": "Ulcerated lesion cure rate at each measurement time point", 
                "safety_issue": "No", 
                "time_frame": "baseline (before the start of treatment), and on Study Days 20, 35 \u00b1 2 days, 49 \u00b1 4 days, 63 \u00b1 7 days, 100 \u00b1 14 days, and 168 \u00b1 14 days"
            }, 
            {
                "description": "(100% re-epithelialization of the index lesion)", 
                "measure": "Median time to initial clinical cure", 
                "safety_issue": "No", 
                "time_frame": "to be determined"
            }, 
            {
                "description": "AEs including application site reactions including elicited examination for pain, and clinician examination for erythema/redness, swelling/edema, and vesicles. Physical examination findings of evidence of mucosal leishmaniasis will be reported as an AE", 
                "measure": "adverse events (AEs) /serious adverse events (SAEs) (clinical signs and symptoms)", 
                "safety_issue": "Yes", 
                "time_frame": "AEs will be assessed at baseline, days 2-9 daily, day 20, day 35, 49, 63, 100, and 168 (if applicable)"
            }, 
            {
                "description": "Any clinically significant changes in lab values from baseline", 
                "measure": "Significant lab abnormalities", 
                "safety_issue": "Yes", 
                "time_frame": "baseline screening and day 20"
            }
        ], 
        "source": "U.S. Army Medical Research and Materiel Command", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "U.S. Army Medical Research and Materiel Command", 
                "agency_class": "U.S. Fed"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}